Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary CNS lymphoma based on 1 of the following:~  * Histologically confirmed non-Hodgkin's B-cell lymphoma by brain biopsy or resection~ * Positive cerebrospinal fluid (CSF) cytology or immunohistochemical diagnosis of CSF monoclonality with or without measurable intracranial disease~ * Histologically confirmed vitreal lymphoma with measurable intracranial tumor~* CD20 positive by brain biopsy~* Measurable (greater than 1 cm in diameter) tumor by CT scan or MRI~* Progressed during first-line chemotherapy and/or radiotherapy OR relapsed after initial successful treatment~* No systemic lymphoma by CT scan of the chest, abdomen, and pelvis with contrast~* No leptomeningeal lymphoma by lumbar puncture for CNS cytology/flow cytometry~* No ocular lymphoma by slit lamp examination~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9.0 g/dL~Hepatic~* Bilirubin less than 1.5 mg/dL~* Transaminases less than 4 times upper limit of normal~Renal~* Creatinine less than 1.5 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 1 year after study participation~* HIV negative~* Mini mental status examination score at least 15~* No concurrent serious infection~* No other medical illness that would preclude study treatment~* No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 90 days since prior biologic therapy~* No prior rituximab~* No concurrent prophylactic growth factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])~Chemotherapy~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* At least 3 months since prior radiotherapy~Surgery~* Not specified~Other~* Recovered from prior therapy~* More than 90 days since prior investigational drugs~* More than 90 days since prior use of a therapeutic device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab monotherapy (Type: EXPERIMENTAL): Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).